SCHEMBL16626232

SCHEMBL16626232

c1ccc(Cc2ccc3nc(-n4cccn4)nc(N4CCOCC4)c3c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 9/20 0.68
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
KDM4E B2RXH2 3/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
MTOR P42345 2/20 0.43
PIK3CA P42336 2/20 0.43
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.42
JAK3 P52333 1/20 0.42
NTRK2 Q16620 1/20 0.42
CAMK2A Q9UQM7 1/20 0.42
PDE5A O76074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16626189 0.90 EGLN1 (0.67) EGLN1ALDH1A1HPGDCYP1A2KDM4E
SCHEMBL14991893 0.86 EGLN1 (0.52) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL16626202 0.86 EGLN1 (0.52) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL16626264 0.84 EGLN1 (0.68) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL622093 0.81 EGLN1 (1.00) EGLN1
SCHEMBL16626234 0.80 KDM4E (0.55) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL16626164 0.80 EGLN1 (0.66) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL16626161 0.79 ALDH1A1 (0.60) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL16626167 0.78 EGLN1 (0.68) EGLN1LMNAHTTALDH1A1HPGD
SCHEMBL627435 0.76 EGLN1 (0.50) EGLN1HTTHPGDGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 2021-04-13 US disclosed
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-03-26 US disclosed
US-9006251-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARAMCEUTICA NV (BE) 2015-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885LMNA 2667/4885HTT 3358/4885
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885LMNA 2667/4885HTT 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.